Adicet Bio Overview

  • Founded
  • 2014
Founded
  • Status
  • Public
  • Employees
  • 82
Employees
  • Stock Symbol
  • ACET
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $12.84
  • (As of Monday Closing)

Adicet Bio General Information

Description

Adicet Bio Inc is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 500 Boylston Street
  • 13th Floor
  • Boston, MA 02116
  • United States
+1 (857) 000-0000

Adicet Bio Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Adicet Bio Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.84 $13.19 $9.71 - $21.40 $419M 31.8M 157K -$5.01

Adicet Bio Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 167,671 167,671
Revenue 17,903 17,903 995 8,181
EBITDA (38,918) (38,918) (27,819) (9,209)
Net Income (36,678) (36,678) (28,138) (9,299)
Total Assets 153,835 153,835 81,587
Total Debt 21,639 21,639 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Adicet Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Adicet Bio Inc is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer
Drug Discovery
Boston, MA
82 As of 2020
00000
000000000000 00000

00000000

itation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000 000

e cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adicet Bio Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
0000000000 0000000 Venture Capital-Backed Mont-Saint-Guibert, Belgium 00 00000 00000000000 00000
You’re viewing 5 of 27 competitors. Get the full list »

Adicet Bio Executive Team (14)

Name Title Board Seat Contact Info
Chen Schor Chief Executive Officer & Board Member
Nick Harvey Chief Financial Officer, Finance
Stewart Abbot Ph.D Chief Scientific Officer & Chief Operating Officer, Operations
Don Healey Ph.D Chief Technology Officer
Carrie Krehlik Senior Vice President and Chief Human Resource Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Adicet Bio Board Members (14)

Name Representing Role Since
Andrew Sinclair Ph.D Self Board Member 000 0000
Asish Xavier Ph.D Johnson & Johnson Innovation - JJDC Board Member 000 0000
Aya Jakobovits Ph.D Adicet Bio Board Member 000 0000
Bastiano Sanna Ph.D Self Board Member 000 0000
Carl Gordon Ph.D Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Adicet Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adicet Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 15-Sep-2020 000000000000000000 0000 Biotechnology 0000 0000000 00.0
Applied Immune Technologies 27-Jan-2016 Merger/Acquisition Drug Discovery 000 0000000000 00.0
To view Adicet Bio’s complete acquisitions history, request access »